Addendum

Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair

Jianli Zhou¹, Drew Sturtevant¹, Cassie Love², Aditya Kulkarni¹, Neha Biyani¹, Umesh Kathad¹, Elizabeth Thacker³, Sandeep Dave² and Kishor Bhatia¹

¹Lantern Pharma Inc., Plano, TX 75024, USA

²Department of Medicine, Duke University, Durham, NC 27708, USA

³Data Driven Bioscience, Durham, NC 27707, USA

Published: July 20, 2023

Copyright: © 2023 Zhou et al. This is an open access article distributed under the terms of the <u>Creative Commons Attribution License</u> (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Wet-lab experiments conducted at Data Driven Bioscience, Rincon Biosciences, Reprocell Inc., intoDNA, and Toxys Europe were funded by Lantern Pharma Inc.

Original article: Oncotarget. 2023; 14:597-611. https://doi.org/10.18632/oncotarget.28454